medisourceasia.com

Industry News


Home

About 
medisourceasia

Magazine
Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info

Contact

 

Aptar Pharma gears up to increase presence in India with a range of nasal & pulmonary devices

Aptar Pharma India Pvt Ltd, a drug delivery device major is gearing up to increase its market presence in the country with its range of pulmonary and nasal drug dispensing products.

With an increasing number of Indian pharma companies introducing products that are delivered through the nasal or pulmonary route there is a clear indication on the huge interest generated for such dispensing devices. In this connection, we are also looking to penetrate into the country further with our range, Kanwal Tikoo, director, Aptar Pharma India Pvt Ltd told Pharmabiz.

Mumbai-based Aptar Pharma India is a wholly-owned subsidiary of the Aptar Group, US. The range of products for the Indian market are Metered Dose Inhalers (MDIs) for pulmonary route and Metered Dose Pumps for Nasal, buccal and dermal routes.

The drug delivery devices market will be $34.5 billion in 2010. Pulmonary delivery is through aerosols, metered dose inhaler systems (MDIs), powders (dry powder inhalers, DPIs) and solutions (nebulizers). Aerosol products for pulmonary delivery comprise more than 30 per cent of the global drug delivery market. Globally the drug delivery devices constitute 2 percent of the pharmaceutical market.

Among the Indian pharma companies which are using such drug delivery devices include Lupin, Glenmark, Cipla, Zydus Cadila, Dr Reddy's, Mcleods Pharma, Midas Care and Biodeal to name a few. Some of these companies are also third party fillers.

Regulatory approvals are required by the pharma companies, but the drug delivery devices are primary packaging component, so the device manufacturers are not obliged to seek regulatory approvals. However, a stringent quality regimen has to be followed during manufacture of such devices to enable pharma companies comply with regulatory requirements with respect to devices they use on their products, stated Tikoo.

Pulmonary drug delivery is viewed as a viable option in respiratory disorders like asthma and chronic obstructive pulmonary disease. The use of devices is also expended for treatment of non-respiratory conditions like diabetes, migraine and osteoporosis. Even dry powder inhalation (DPI), is much-sought-after in the non-invasive drug delivery process.

Companies are also beginning to explore the benefits of nasal drug delivery as an alternative to oral or injectable methods of delivering systemic drugs for a variety of diseases. Around two per cent of the overall drug delivery is administered via the nasal route. Vaccines are also a growing area of interest for nasal drug delivery.

In India too, drug delivery devices constitute around two per cent of the Rs 44,000 crore Indian pharma market. Other well-known global drug delivery device companies are 3M and Bespak.

(Ref: The Chronicle Pharmabiz dated August 22, 2009)

Pharmexcil Constitutes Export Awards For Indian Pharma Companies

In order to encourage the export activities of the Indian pharma companies, the Pharmaceutical Exports Promotion Council (Pharmexcil) is in the process of introducing exports awards to the companies which has demonstrated outstanding export performance in the last four years.

The Council has invited applications from pharma exporters in the country and will commence the selection process for the best performance under a separate committee of experts after August 25, 2009. The awards will be presented to the winners in the Annual General Meeting (AGM) of the Council, which will be held in September 2009, informs Dr P V Appaji, executive director, Pharmexcil.

"We have tried to introduce such a recognition to the companies earlier too. But the response from the industry was very poor at that time. Now, we have received a good response. We will also try to collect company-wise exports data from the central government to identify the eligible company though they have not applied for the award," he said. "The recognition from the council would encourage the companies to boost their exports performance in future," Appaji said.

The awards will be distributed for two categories - General Category and Product Category and there will be one trophy and one merit certificates and one award for emerging exporter in each of the category. Awards will be bestowed for the best performance for the years 2005-06, 2006-07, 2007-08 and 2008-09. The Council is also planning to present the awards annually at its AGM from next year onwards.

The Council will accept application forms for the awards till August 25, 2009 and will forward it to the expert committee appointed by the Committee of Administration for their recommendations.

(Ref: The Chronicle Pharmabiz dated August 21, 2009)

Other News

Ahmedabad Likely To Get First National Medical Device Centre
Essel Propack Medical Biz Up For Sale
Ethicon introduces new packaging for Biopatch to improve ease of application for patients with catheters

Archives

Advertisement

 

 


Back | Back To Top | Previous